Cumberland pharmaceuticals reports 17% revenue growth for the full year 2019

Cumberland pharmaceuticals reports 17% revenue growth for the full year 2019.q4 adjusted earnings per share $0.09.q4 revenue rose 1 percent to $13.7 million.received fda approval for reditrex.cumberland pharmaceuticals - initiated new ifetroban clinical program.cumberland pharmaceuticals - qtrly loss per share $0.06.
CPIX Ratings Summary
CPIX Quant Ranking